This week Moderna, Inc. announced that the UK regulator, the MHRA, had begun a rolling review of its COVID-19 vaccine candidate, mRNA-1273. The company is also planning to file the product with the European Medicines Agency, and has begun a rolling submission to Health Canada.
The announcement of the UK review follows the publication of positive results of a preclinical viral challenge of mRNA-1273 and the positive interim analysis of the Phase I study of the vaccine in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?